Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
190 Results for "
Cyclic AMP
" in MedChemExpress (MCE) Product Catalog:
Products (190)
190 Results for "Cyclic AMP" in MCE Product Catalog:
192
192 Publications Verification
Cat. No.: HY-15979
CAS No.: 127243-85-0
Research Areas:
H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.
86
Target:
Research Areas:
RU.521 (RU320521) is a potent and selective cyclic GMP-AMP synthase (cGAS) inhibitor and inhibits cGAS-mediated interferon upregulation. RU.521 suppresses dsDNA-activated reporter activity with an IC50 of 0.7 μM. RU.521 reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome (AGS) .
68
68 Cited Publications
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
42
42 Cited Publications
Synonyms: 2'-3'-Cyclic GMP-AMP
Target:
42
42 Cited Publications
Synonyms: 2'-3'-Cyclic GMP-AMP sodium
Target:
39
39 Cited Publications
Synonyms: 8-Br-CAMP sodium salt
8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells .
39
8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells .
30
30 Cited Publications
Synonyms: Cyclic adenosine monophosphate; Adenosine Cyclic 3', 5'-monophosphate; cAMP
Category:
Natural Products Microorganisms Other Diseases Endogenous metabolite Disease Research Fields
Target:
30
30 Cited Publications
Cat. No.: HY-B1511A
CAS No.: 37839-81-9
Synonyms: Cyclic adenosine monophosphate sodium; Adenosine Cyclic 3', 5'-monophosphate sodium; cAMP sodium
27
27 Cited Publications
Synonyms: Cyclic GMP-AMP; 3',3'-cGAMP
Target:
Research Areas:
cGAMP (Cyclic GMP-AMP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
27
27 Cited Publications
Synonyms: Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium
Category:
Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Inflammation/Immunology
Target:
27
27 Cited Publications
Cat. No.: HY-110385A
Purity: 95.19%
Synonyms: Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium
Target:
19
19 Cited Publications
Cat. No.: HY-12326A
CAS No.: 2734909-87-4
Synonyms: Cyclic diadenylate disodium; Cyclic-di-AMP disodium
Target:
19
19 Cited Publications
Cat. No.: HY-12326B
Purity: 99.36%
Synonyms: Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium
Target:
10
Target:
Research Areas:
Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
8
8 Cited Publications
Target:
Research Areas:
G150 is a highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with an IC50 of 10.2 nM. G150 represses dsDNA-triggered interferon expression, and G150 can be used for the research of inflammatory .
8
Category:
Infection Microorganisms Antibiotics Disease Research Anticancer Disease Research Fields Other Antibiotics
Target:
7
7 Cited Publications
Target:
Research Areas:
G140 is a potent and selective inhibitor of cyclic GMP-AMP synthase (cGAS), with IC50s of 14.0 nM and 442 nM for h-cGAS and m-cGAS, respectively. G140 has anti-inflammatory activity .
7
Research Areas:
Famotidine (MK-208) is an orally active and highly selective histamine H2 receptor antagonist. It inhibits gastric acid secretion by blocking the Gs signaling pathway, and regulates intracellular cAMP and ERK pathways. Famotidine inhibits TLR3-mediated inflammatory pathways, and reduces the expression of various inflammatory mediators and interferon-related genes. Famotidine scavenges DPPH and nitric oxide free radicals, alleviates oxidative stress damage in gastric tissue, inhibits proMMP-9, improves vascular endothelial permeability, and restores the normal physiological functions of neutrophils and eosinophils. Famotidine crosses intestinal epithelial cells via facilitated diffusion and passive diffusion, blocks paracellular cation transport, and increases intestinal transepithelial electrical resistance. Famotidine reduces serum levels of transaminases and alkaline phosphatase, exerts analgesic effects and gastric protective effects simultaneously. Famotidine can be used in studies related to COVID-19, liver injury and acute gastric ulcer .
3
3 Cited Publications
Target:
Research Areas:
PF-06928215 is a cGAS (cyclic GMP-AMP Synthase) inhibitor with an IC50 of 4.9 μΜ. PF-06928215 has a high binding affinity of 0.2 μM (Kd) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
